Skip to main content

Tumor-infiltrating Lymphocytes (TIL)

CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

  • RegistryNCT05681780
  • PhasePhase 1
  • StatusRecruiting
  • ConditionNon Small Cell Lung Cancer
  • SponsorH. Lee Moffitt Cancer Center and Research Institute
How Tumor-infiltrating Lymphocytes (TIL) worksNCT056817801 min

What the film says

Read the transcript

Some lung cancers are driven by one broken gene: EGFR, ALK, ROS1, or HER2. Targeted pills work, for a while. When they stop, immunotherapy rarely helps.

The idea: the few immune cells that did find the tumor are the right ones. Grow them into an army.

Surgeons remove a piece of tumor. In the lab, the T cells inside it are pulled out, sharpened with a signal called CD40 ligand, and multiplied into billions. After chemotherapy clears space, they return by infusion, with nivolumab to keep them switched on.

In Moffitt's earlier lung trial, tumors shrank in eleven of thirteen patients. This trial, led by Ben Creelan, asks whether it is safe in gene-driven cancers. Public record; not medical advice.

Sources behind this film

Show 1 more sources

The drug

What is being tested.

Tumor harvest for TIL growth in the lab: A sample of the participant's tumor will be collected and sent to the lab for TIL growth. TIL will be prepared and cryopreserved.

On day 0, all patients will receive a dose infusion TIL cells.

The study

How the trial runs.

To determine the effect of a special preparation of cells, called tumor-infiltrating lymphocytes (TIL) stimulated with CD40L, when given with the drug nivolumab, for patients with EGFR, ALK, ROS1, or HER2-genomically altered lung cancer.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Age greater than or equal to 18 years
  • Diagnosis of stage IV or recurrent non-small cell lung cancer (NSCLC) with an activating genomic alteration within either: EGFR, ALK, ROS1, or ERBB2 receptor tyrosine kinase domains
  • ECOG performance status of 0 or 1
  • Expected survival ≥ 4 months
  • Participants must have had disease progression after at least one prior line of systemic therapy for NSCLC, including appropriate prior targeted therapy for cases in which a targeted therapy is conventionally used for this genomic alteration, prior to initiating nivolumab trial therapy
  • Measurable disease, not including any lesion that is used for TIL harvest, prior to initiation of nivolumab trial therapy

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.